Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Two Chinese nationals have been indicted for hacking into the computer systems of hundreds of companies, governments, non-governmental organizations and more to steal trade secrets, including data on treatments related to COVID-19.
In addition, the Phase II CRESTONE study has begun, examining the efficacy and safety of seribantumab in patients with solid tumors that feature a neuregulin-1 (NRG1) fusion.
In an ongoing online hearing before the House Committee on Energy and Commerce’s Oversight and Investigation subcommittee, executives from across the pharmaceutical industry outlined the steps their companies are taking to combat COVID-19 and restore the world to a sense of normalcy.
Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs earlier this year with a goal of reframing the understanding of the body’s organismal and cellular performance.
Oxford University, which by many standards is ahead of everyone in the vaccine development world, is suggesting end of the year is possible, but being very cautious about it.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
Forge Biologics is a viral vector contract development manufacturing organization (CDMO) and therapeutics developer.
The trial was initially scheduled for July, but in April had been postponed until October due to the pandemic. A final decision will be made in August.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.